“Over the past 13 years, I had the greatest opportunity to exploit my passion for science at IPST by contributing to the design, and validation of unique assays which are now routinely run and serve to quantify the efficacy in preclinical drug candidates. My greatest contribution was to see the increase in demand for efficacy services such as the rodent model of pulmonary arterial hypertension (PAH), as well as our intravascular thrombosis and hemostasis models.” Charles completed his doctorate in Pharmacology at the Université de Montreal followed by 4 years of post doctorate studies at the University of Pittsburgh in the Department of Molecular Genetics and Biochemistry. His field of expertise includes cardiovascular pharmacology and molecular biology.
Connect with Charles-E. Laurent
Plasma Protein Binding Assay
Purpose
Determine the free vs. bound ratio of test article in human blood using an equilibrium dialysis assay.
Method
The equilibrium dialysis method uses an equilibrium dialysis device with an 8K molecular weight cut-off membrane to prevent proteins and protein-bound test article from crossing the dialysis membrane; serum remains on one side of the membrane while buffer and free test article crosses to the other side. Once provided with the concentration measurement results, IPST will calculate the percentage of free and protein-bound test article.
Study outcome
Percentage free and bound test article following incubation in human serum.
Compliance
Non-GLP compliant. The study is best suited to quantify the bioavailability of test article.
Charles-E. Laurent
Ph.D., Director of In-Vivo Pharmacology
